We showed that JNJ-527 is a CNS-penetrant CSF1R inhibitor and established an optimal dose for preclinical applications, and estimate an efficacious dose for further clinical investigations in neurodegenerative disease. This evidence concerns the gene CSF1R and neurodegenerative disease.